(4-呋喃-2-基-[4,5]双嘧啶-2-基)-吡啶-3-胺 | 851371-22-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: (4-呋喃-2-基-[4,5]双嘧啶-2-基)-吡啶-3-胺
• 英文名称: LAS 38096
• 英文别名: 4-(furan-2-yl)-N-pyridin-3-yl-5-pyrimidin-4-ylpyrimidin-2-amine；LAS38096；4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine；Unii-168SF9F04E
• CAS: 851371-22-7
• 化学式: C₁₇H₁₂N₆O
• 分子量: 316.322
• InChiKey: YRPIMMMBNUUYLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89.6
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 海关编码：
  2934999090

制备方法与用途

LAS38096是一种强效、选择性且有效的A2B腺苷受体拮抗剂，其Ki值为17纳摩尔。

反应信息

• 作为产物：
  描述：

  4-甲基嘧啶 在 tris(dibenzylideneacetone)dipalladium (0) 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 potassium carbonate 、 caesium carbonate 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 45.0h， 生成 (4-呋喃-2-基-[4,5]双嘧啶-2-基)-吡啶-3-胺
  参考文献：
  名称：

  Discovery and Characterization of 4‘-(2-Furyl)-N-pyridin-3-yl-4,5‘-bipyrimidin-2‘-amine (LAS38096), a Potent, Selective, and Efficacious A_2B Adenosine Receptor Antagonist

  摘要：

  A novel series of N-heteroaryl 4'-(2-furyl)-4,5'-bipyrimidin-2'-amines has been identified as potent and selective A(2B) adenosine receptor antagonists. In particular, compound 5 showed high affinity for the A(2B) receptor (K-i = 17 nM), good selectivity (IC50: A(1) > 1000 nM, A(2A) > 2500 nM, A(3) > 1000 nM), displayed a favorable pharmacokinetic profile in preclinical species, and showed efficacy in functional in vitro models.

  DOI：

  10.1021/jm061333v

文献信息

• [EN] PYRIMIDIN-2-AMINE DERIVATES AND THEIR USE AS A2B ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PYRIMIDIN-2-AMINE ET UTILISATION DE CEUX-CI EN TANT QU'ANTAGONISTES DU RECEPTEUR DE L'ADENOSINE A2B
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2005040155A1

  公开（公告）日：2005-05-06

  This invention is directed to new potent and selective antagonists of the A2B adenosine receptor having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  本发明涉及新型强效选择性A2B腺苷受体拮抗剂，其具有一般式(I)，以及其制备方法；涉及包含它们的药物组合物；以及它们在治疗中的应用。
• Pyrimidin-2-Amine Derivatives and Their Use as A2b Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20070265273A1

  公开（公告）日：2007-11-15

  This invention is directed to new potent and selective antagonists of the A 2B adenosine receptor having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  本发明涉及一种新型的A2B腺苷受体具有一般式(I)的高效选择性拮抗剂，以及它们的制备方法、包含它们的药物组合物和它们在治疗中的应用。
• [EN] REDUCING DIABETES IN PATIENTS RECEIVING HMG-COA REDUCTASE INHIBITORS (STATINS)<br/>[FR] RÉDUCTION DE DIABÈTE CHEZ DES PATIENTS RECEVANT DES INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)
  申请人：JOLLA INST ALLERGY IMMUNOLOG

  公开号：WO2014153424A1

  公开（公告）日：2014-09-25

  The invention provides compositions, methods and uses for reducing insulin resistance or risk of diabetes in a subject taking a statin. The invention also provides compositions, methods and uses for reducing or decreasing increases in blood glucose caused by a statin in a subject taking a statin. The invention further provides compositions, methods and uses for reducing insulin resistance or risk of diabetes in a subject taking statins, and for treating diabetes in a subject taking statins. The invention moreover provides compositions, including an adenosine receptor antagonist, and/or an A2B receptor antagonist, and/or a CD73 antagonist and a statin.